局部区域低剂量白细胞介素-2用于胃肠道肿瘤的治疗
Locoregional IL-2 low dose applications for gastrointestinal tumors.
作者信息
Krastev Zachary, Koltchakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Koten Jan-Willem, Jacobs John, Den Otter Willem
机构信息
Clinic of Gastroenterology, University Hospital, Bulgaria.
出版信息
World J Gastroenterol. 2005 Sep 21;11(35):5525-9. doi: 10.3748/wjg.v11.i35.5525.
AIM
To explore the feasibility of local interleukin 2 (IL-2) in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application.
METHODS
Sixteen patients with stages III and IV of gastrointestinal malignancies (primary or metastatic) who were admitted to our Department of Gastroenterology were treated with locoregionally applied IL-2 in low doses.
RESULTS
No major problems applying locoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition.
CONCLUSION
This study demonstrates the feasibility of low dose locoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.
目的
探讨局部应用白细胞介素2（IL-2）治疗不同类型腹部癌症患者的可行性。这需要对IL-2应用的时间间隔和应用方法进行实验。
方法
16例入住我院消化内科的胃肠道恶性肿瘤（原发性或转移性）Ⅲ期和Ⅳ期患者接受了低剂量局部应用IL-2治疗。
结果
局部应用IL-2未遇到重大问题。16例患者中有6例获得了适度但具有临床价值的改善。不良反应极小。即使是病情较差的患者，该治疗方案的耐受性也良好。
结论
本研究证明了低剂量局部应用IL-2治疗晚期腹部癌症的可行性。局部IL-2治疗的不良反应微乎其微。结果表明，瘤内应用很重要。局部IL-2可作为标准治疗方案的辅助治疗，且无需复杂的手术干预。这些初步结果令人鼓舞。
Zotero 插件